

## Bibliografía

- Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*. 2020;6:16, <http://dx.doi.org/10.1038/s41421-020-0156-0>.
- Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;105949, <http://dx.doi.org/10.1016/j.ijantimicag.2020.105949>.
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020;30:269–71, <http://dx.doi.org/10.1038/s41422-020-0282-0>.
- Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. *Drug Metabol Drug Interact*. 1997;14:55–82.
- Tiberghien F, Loo F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. *Anticancer Drugs*. 1996;7:568–78, <http://dx.doi.org/10.1097/00001813-199607000-00012>.
- Verde Z, de Diego LG, Chicharro LM, Bandrés F, Velasco V, Mingo T, et al. Physical performance and quality of life in older adults: is there any association between them and potential drug interactions in polymedicated octogenarians. *Int J Environ Res Public Health*. 2019;16, <http://dx.doi.org/10.3390/ijerph16214190>.
- Food and Drug Administration. Chloroquine Phosphate Tablets West-ward. n.d.
- Carroll C, Hassanin A. Polypharmacy in the elderly-when good drugs lead to bad outcomes: a teachable moment. *JAMA Intern Med*. 2017;177:871, <http://dx.doi.org/10.1001/jamainternmed.2017.0911>.
- Giner-Soriano M, Casajuana M, Roso-Llorach A, Vedia C, Morros R. Effectiveness, safety and costs of stroke prevention in non-valvular atrial fibrillation. Study of cohorts matched by Propensity score. *Aten Primaria*. 2020;52:176–84, <http://dx.doi.org/10.1016/j.aprim.2019.06.002>.
- Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly Bailliere's. *Best Pract Res Clin Gastroenterol*. 2001;15:897–918, <http://dx.doi.org/10.1053/bega.2001.0249>.
- Liverpool Drug Interaction Group. Liverpool COVID-19 Interactions n.d. <http://www.covid19-druginteractions.org/> [accessed 26.03.20].
- Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. *Lancet Neurol*. 2003;2:347–56, [http://dx.doi.org/10.1016/S1474-4422\(03\)00409-5](http://dx.doi.org/10.1016/S1474-4422(03)00409-5).
- Perucca E. Clinically relevant drug interactions with antiepileptic drugs. *Br J Clin Pharmacol*. 2006;61:246–55, <http://dx.doi.org/10.1111/j.1365-2125.2005.02529.x>.
- Ahmad Diaz F, Castello Noria A, Bielsa Martin S, Schoenenberger Arnaiz J. Exacerbation of a systemic autoimmune disease as a result of the onset of a tuberculosis treatment. *Aten Farm*. 2012;14:56–8.
- Range FT, Hilker E, Breithardt G, Buerke B, Lebedez P. Amiodarone-induced pulmonary toxicity – a fatal case report and literature review. *Cardiovasc Drugs Ther*. 2013;27:247–54, <http://dx.doi.org/10.1007/s10557-013-6446-0>.
- Miranda-Aquino T, Pérez-Topete, Silvia Esmeralda Ortega-Pantoja W, Gómez-Vázquez, Carlos Alejandro Meneses-Pérez, Luis Gilberto González-Padilla C, et al. Long QT syndrome secondary to drug interaction between hydroxychloroquine and amiodarone. *Rev Mex Cardiol [Online]*. 2018;29:98–101.
- Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. *Pharmacother J Hum Pharmacol Drug Ther*. 2017;37:236–48, <http://dx.doi.org/10.1002/phar.1884>.
- Leden I. Digoxin-hydroxychloroquine interaction? *Acta Med Scand*. 2009;211:411–2, <http://dx.doi.org/10.1111/j.0954-6820.1982.tb01971.x>.
- Rochester MP, Kane AM, Linnebur SA, Fixen DR. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. *Ther Adv Drug Saf*. 2018;9:297–308, <http://dx.doi.org/10.1177/2042098618772979>.
- Wiśniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect – comprehensive overview of clinical trials. *BMC Pharmacol Toxicol*. 2016;17:1–15, <http://dx.doi.org/10.1186/s40360-016-0053-1>.

Verónica Velasco-González<sup>a,b,c</sup>, Ana Fernández-Araque<sup>b,d</sup>,  
 María Sainz-Gil<sup>b,e</sup>, Natalia Jimeno<sup>b,f</sup>, Luis H. Martín<sup>a,e</sup>,  
 Zoraida Verde<sup>b,g,\*</sup>

<sup>a</sup> Department of Nursery, University of Valladolid, Valladolid, Spain

<sup>b</sup> Recognized research group "Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoeconomics", University of Valladolid, Valladolid, Spain

<sup>c</sup> Institute of Applied Ophthalmobiology, University of Valladolid, Valladolid, Spain

<sup>d</sup> Department of Nursery, University of Valladolid, Campus Duques de Soria, Soria, Spain

<sup>e</sup> Centre for Castilla y Leon Pharmacovigilance, Valladolid, Spain

<sup>f</sup> Department of Psychiatry, University of Valladolid, Valladolid, Spain

<sup>g</sup> Department of Biochemistry, Molecular Biology and Physiology, University of Valladolid, Campus Duques de Soria, Soria, Spain

\* Corresponding author.

E-mail address: [zoraida.verde@uva.es](mailto:zoraida.verde@uva.es) (Z. Verde).

<https://doi.org/10.1016/j.arbres.2020.06.001>

0300-2896/ © 2020 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Repeatability of Circulating Eosinophil Measures and Inhaled Corticosteroids Effect in Bronchiectasis. A Post Hoc Analysis of a Randomized Clinical Trial



### Repetibilidad de las mediciones de eosinófilos circulantes y el efecto de los corticosteroides inhalados en las bronquiectasias. Un análisis a posteriori de un ensayo clínico aleatorizado


Dear Editor:

Peripheral eosinophils can increase in case of allergic, parasitic, or auto-immune disorders. Absolute and relative counts of peripheral eosinophils have been proposed to prescribe drugs in asthmatic patients and to assess their effectiveness.<sup>1</sup> Their assessment was also suggested in individuals with chronic obstructive pulmonary disease (COPD). Eosinophils counts >300 cells/μL or >3% have been associated with a higher incidence and severity of exacerbations but with a better response to inhaled corticosteroids (ICs).<sup>2</sup> On the other hand, counts <100 eosinophils/μL (<2%) has been associated with poor therapeutic response to ICs and a high incidence of adverse events (e.g., pneumonia).<sup>3</sup>

There is very scarce literature on the role played by peripheral eosinophils in patients with bronchiectasis. It is known that

bronchiectasis patients have a higher eosinophil counts in bronchial mucosa in comparison with healthy subjects and, sometimes, an eosinophilic pattern can be the predominant inflammatory cell type in the sputum.<sup>4</sup> Keeping into account the bactericidal activity of eosinophils,<sup>5</sup> the prognostic value of bronchial bacterial infection and its association with eosinophil counts,<sup>6</sup> and the potential immunosuppressive effect of ICs, an interaction between peripheral eosinophils and ICs treatment could be hypothesized also in bronchiectasis. Only one small study conducted by Aliberti et al. found that bronchiectasis patients treated with ICs can show a significant improvement of quality of life only when eosinophilia (at least 150 cells/L or ≥3%) is found.<sup>7</sup>

Usually, baseline counts of circulating eosinophils in patients with clinical stability is used to predict long-term prognosis and therapeutic response, following the demonstration of a correlation between lung tissue and circulating eosinophil counts.<sup>8</sup> However, peripheral eosinophils can fluctuate overtime because of their short half-life and diurnal variation (e.g., peak in the evening).<sup>9</sup> Therefore, before their assessment as a biomarker in large studies in bronchiectasis, it is key to evaluate their time stability, as well as the role played by ICs at different dosages. A randomized controlled trial (RCT) published in 2008 evaluated the effectiveness of ICs in patients with bronchiectasis and performed repeated measures of eosinophils at different time-points.<sup>10</sup>



**Fig. 1.** (A) Correlation graphs comparing 2-by-2 groups from circulating eosinophil baseline measures to 24-weeks follow-up measures. (B) Mean (standard deviation) eosinophils percentage counts at baseline, 4, 12 and 24 weeks in the studied groups. ICC: intraclass correlation coefficient; ICs: inhaled corticosteroids.

The objective of the present study was to assess the variability of circulating eosinophils overtime retrieving data from that RCT, as well as to prove ICs effect on this variability when prescribed at different dosages.

The RCT recruited 132 patients with bronchiectasis diagnosed through high-resolution CT scan. Patients with cystic fibrosis, asthma, allergic bronchopulmonary aspergillosis, those exposed to systemic steroids or immunosuppressive therapy, or suffering from eosinophilic pulmonary or systemic diseases were excluded. Finally, 86 were randomized and followed-up for the entire duration of the study. All randomized patients were not exposed to ICs in the three months before their enrollment. A total of 28 patients did not receive ICs, 29 were treated with 250 µg of fluticasone propionate (FP) bid (medium doses), and 29 were exposed to 500 µg of FP bid (high doses) for 6 months. Blood collection was performed in the early morning and during a clinical stability state ( $\geq 4$  weeks after an exacerbation).

Intraclass correlation coefficient (ICC) (95%CI) was computed to assess eosinophilic counts stability, comparing baseline values with those recorded after 1, 3, and 6 months. Values ranging from 0.41 to 0.60 represented a moderate concordance, whereas those  $>0.60$  a good concordance.<sup>11</sup> Normal distribution of the variables was assessed by the Kolmogorov–Smirnov test. Pearson correlation coefficient was calculated. To assess the effect of the ICs on eosinophil counts changes, an ANOVA for repeated measures with the Bonferroni correction for multiple comparisons was performed. In 25 (7.8%) cases a multiple imputation method by chained equations was implemented under the assumption that missing data were missing randomly. A  $p$ -value  $<0.05$  was considered statistically significant. Statistical computations were performed with the statistical package SPSS (version 20.0).

86 patients [mean (SD) age: 69.5 (8.9) years; 64% were women] were randomly selected. 21% were infected by *Pseudomonas aeruginosa*. At baseline mean (SD) FEV<sub>1</sub> was 1403 (557) mL, and mean (SD)

eosinophil percentage was 2.97 (1.3)%. A total of 74.4% and 41.8% patients had an eosinophil percentage of  $>2\%$  and  $>3\%$  at baseline, respectively, whereas 74.4% and 34.9% after 6 months of therapy. No statistically significant differences were found between the three groups.<sup>10</sup>

Fig. 1 shows higher ICC values in cases of closer measurements until 12 weeks, but lower in those at 24 weeks. Those results are confirmed by the correlation analysis showed in the same figure. 81% and 48.6% of patients did not change their eosinophil percentage  $>2\%$  and  $>3\%$  after 6 months, respectively. There were no differences between eosinophil percentage counts between groups at any time ( $p$  values between 0.31 and 0.69 at baseline, 4, 12 and 24 weeks). Finally, it was not proved any significant effect of ICs treatment or its doses over time (intergroup  $p$  value: 0.83).

The results found in patients with bronchiectasis overlap those found in COPD patients. A study on 27,557 patients with stable COPD showed an ICC of 0.61.<sup>12</sup> However, a post hoc analysis of TRISTAN proved variability between baseline and 24- and 52-week values.<sup>13</sup> Moreover, in our study  $>80\%$  of patients remained with  $>2\%$  of eosinophils at 6 months of follow-up, but less than 50% remained with  $>3\%$  compare with baseline data, as it was also found in COPD.<sup>14</sup> Similarly, although circulating eosinophils seem to be a good biomarker for the assessment of the effectiveness of ICs in preventing exacerbations,<sup>3</sup> their values is not affected by ICs in COPD patients.<sup>15</sup> The results of this study highlight the necessity of performing repeated measures of eosinophils in the design of long-term studies to assess the role of this biomarker in clinical outcomes and treatment effectiveness in bronchiectasis.

In conclusion, moderate to good concordance between baseline and follow-up eosinophil counts was showed in patients with bronchiectasis. However, this concordance can decrease at six months but it is not affected by ICs treatment or its doses.

## Previous presentations

This data have not been presented in any scientific congress or meeting

## Funding

This study has no funding.

## Conflict of interest

The authors declare no conflict of interest.

## Bibliografía

1. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*. 2012;380:651–9.
2. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med*. 2015;3:435–42.
3. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. *Lancet Respir Med*. 2016;4:731–41.
4. Tsikrika S, Dimakou K, Papaioannou AI, Hillas 4, Thanos L, Kostikas K, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. *Cytokine*. 2017;99:281–6.
5. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. *J Immunol (Baltimore, Md: 1950)*. 1989;142:4428–34.
6. Kolsum U, Donaldson GC, Singh R, Barker BL, Gupta V, George L, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. *Respir Res*. 2017;18:88.
7. Aliberti S, Sotgiu G, Blasi F, Sadari L, Posadas T, Martinez-Garcia MA. Blood eosinophils predict inhaled fluticasone response to bronchiectasis. *Eur Resp J*. 2020. <http://dx.doi.org/10.1183/13993003.00453-2020>.
8. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. *Am J Respir Crit Care Med*. 2011;184:662–71.
9. Szeffler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. Asthma outcomes: biomarkers. *J Allergy Clin Immunol*. 2012;129 Suppl. 3:S9–23.
10. Martinez-Garcia MA, Perpiña M, Román P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. *Resp Med*. 2006;100:1623–32.
11. Kramer MS, Feinstein AR. Clinical biostatistics LIV. The biostatistics of concordance. *Clin Pharmacol Ther*. 1981;111–23.
12. Landis S, Suruki R, Bonar K, Hilton E, Compton C. Blood eosinophil levels in COPD patients in the UK Clinical Practice Research Datalink (CPRD). *Am J Respir Crit Care Med*. 2016;193:A6329.
13. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. *Thorax*. 2016;71:118–25.
14. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. *Eur Respir J*. 2014;44:1697–700.
15. Tine M, Biondini D, Semenzato U, Bazzan E, Cosio MG, Saetta M, et al. Reassessing the role of eosinophils as a biomarker in chronic obstructive pulmonary disease. *J Clin Med*. 2019;8:962.

Miguel Angel Martinez-Garcia<sup>a,\*</sup>, Tomás Posadas<sup>a</sup>, Giovanni Sotgiu<sup>b</sup>, Francesco Blasi<sup>c,d</sup>, Laura Sadari<sup>b</sup>, Stefano Aliberti<sup>c,d</sup>

<sup>a</sup> *Pneumology Department, Hospital Universitario i Politécnico La Fe, Valencia, Spain*

<sup>b</sup> *Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy*

<sup>c</sup> *University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy*

<sup>d</sup> *Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy*

\* Corresponding author.

E-mail address: [mianmartinezgarcia@gmail.com](mailto:mianmartinezgarcia@gmail.com)

(M.A. Martinez-Garcia).

<https://doi.org/10.1016/j.arbres.2020.06.005>

0300-2896/ © 2020 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.